A new PD-L1 inhibitor may be on the horizon for people with malignant mesothelioma. A Phase I trial suggests it may be safer than some previous immunotherapy drugs. PD-L1 is a protein that helps mesothelioma cancer cells hide from the immune system. Several of the most promising immunotherapy drugs for mesothelioma block PD-L1. But the new PD-L1 inhibitor is different. CX-072 (pacmilimab) has the ability to specifically target the tumor. This could reduce the risk for dangerous side effects since normal cells are less likely to be affected. San Francisco-based CytomX Therapeutics developed CX-072 and a team of international researchers has been studying it. This week, they released the findings of their Phase I trial. The trial included patients with … Continue reading New PD-L1 Inhibitor Could Make Mesothelioma Immunotherapy Safer
If you experienced asbestos exposure more than 30 years ago and you have not developed mesothelioma, your risk for the disease may be starting to decline. A new Italian study is the latest to suggest that mesothelioma risk may taper off over time. A group of occupational health experts conducted the study. Their goal was to predict mesothelioma trends in Italy until 2040. The data shows that mesothelioma cases will probably peak this year. But they also show that most of those cases will happen in people with asbestos exposure in the last three decades. Asbestos Exposure and Mesothelioma Incidence Asbestos is the main cause of malignant mesothelioma. A small number of mesothelioma cases happen without any known asbestos exposure. … Continue reading How Long Does Mesothelioma Risk Last After Asbestos Exposure?
An international research study including patients from 11 countries may help reveal new and better ways to predict peritoneal mesothelioma prognosis. Right now, doctors use three primary criteria to determine peritoneal mesothelioma prognosis. Those are how much cancer was in the abdomen at the time of surgery, how complete the surgery was, and the tumor grade. But about 70 percent of people treated for peritoneal cancers like mesothelioma have recurrent disease. The goal of the new study is to find more prognostic factors. Knowing these factors could help doctors make better choices about which patients are most likely to benefit from cytoreductive surgery (CRS). The CRS/HIPEC Procedure for Mesothelioma Peritoneal mesothelioma occurs on the lining of the abdomen. Peritoneal mesothelioma … Continue reading Peritoneal Mesothelioma Prognosis: Searching for New Factors
A new report out of South Korea is proof that it can take many years for mesothelioma rates to decline even after implementing an asbestos ban. Asbestos is the number one cause of malignant mesothelioma worldwide. South Korea banned asbestos in 2009. But a report in the International Journal of Environmental Research and Public Health shows the country will likely be dealing with the after-effects well into the future. A national asbestos ban is a vital step toward fighting occupational cancer. But the new study is a sobering reminder that it cannot eliminate mesothelioma overnight. Occupational Risk for Malignant Mesothelioma Mesothelioma can be a health hazard for anyone who ever worked with or around asbestos. Once a worker inhales or … Continue reading South Korean Mesothelioma Rates Still Rising Decades After Asbestos Ban
New research conducted in Europe and at Harvard University may open the door to safer immunotherapy for mesothelioma patients. Immunotherapy is one of the most promising approaches to fight malignant mesothelioma. But the potential side effects can be devastating. Now, new data suggests there are ways to reduce the complications of immunotherapy for mesothelioma. The key is to target some of the white blood cells that trigger inflammation. Inflammation is the driver behind most of the serious side effects of immunotherapy. Why Harness the Immune System? No one ever expects to contract mesothelioma. It is an extremely rare cancer. Most people who get it have spent time living or working around asbestos. Even among asbestos-exposed people, mesothelioma is rare. Scientists … Continue reading Study May Lead to Safer Immunotherapy for Mesothelioma
A new study suggests that treatment with vinorelbine may boost progression free survival for people with relapsed malignant mesothelioma. Mesothelioma is a virulent cancer caused by exposure to asbestos. Chemotherapy is the primary first-line treatment. But this cancer almost always comes back within a few months. Now, researchers at the UK’s University of Leicester say treatment with vinorelbine might keep mesothelioma at bay for several months longer. They presented their research at this months’ annual meeting of the American Society of Clinical Oncology. Second-Line Mesothelioma Treatments Needed Pleural mesothelioma is the most common form of mesothelioma. Tumors grow on the membrane around the lungs. The symptoms often mimic lung cancer but can be even more deadly. Some of the healthiest … Continue reading Treatment with Vinorelbine for Relapsed Pleural Mesothelioma
A protein called CDLN15 could be a novel diagnostic marker for malignant pleural mesothelioma, allowing doctors to pinpoint asbestos cancer earlier and boost the odds of survival. That is the message from a recently published Japanese study. Pleural mesothelioma is notoriously difficult to diagnose. It rarely causes any symptoms at all until it is in a late stage. When the symptoms do show up, they are easy to confuse with other illnesses. Earlier diagnosis of pleural mesothelioma depends on finding things that set it apart from other diseases. This novel diagnostic marker could serve as a red flag for this rare but deadly cancer. CDLN15 as a Novel Diagnostic Marker CDLN15 stands for claudin-15. Claudins are a family of proteins … Continue reading Japanese Researchers Discover ‘Novel Diagnostic Marker’ for Mesothelioma
There is more evidence that artificial intelligence may have a role to play in helping doctors diagnose deadly malignant mesothelioma earlier. A study conducted at Japan’s Hyogo College of Medicine used past patient records to test a deep convolutional neural network (CDNN). This is a complex computer program designed to evaluate diagnostic criteria. Pleural mesothelioma is a difficult cancer for doctors to diagnose. Artificial intelligence can help by quickly comparing diagnostic data to hundreds of past cases. In the Japanese study, the AI produced the most accurate mesothelioma diagnoses when combined with all of the available patient data. The Challenge of Diagnosing Mesothelioma Mesothelioma tumors grow on the membranes around internal organs. They usually come from past exposure to asbestos. … Continue reading Artificial Intelligence Improves Mesothelioma Diagnosis, Study Finds
A new Spanish report concludes that banning asbestos is the most effective way to prevent new cases of mesothelioma and asbestos-linked lung cancer. Experts in epidemiology and occupational health conducted the research. Their report appears in a recent issue of the Spanish medical journal, Gaceta Sanitaria. The research shows that all types of asbestos raise the risk for lung cancer and mesothelioma and that some are extra dangerous. The study found that people exposed to needle-shaped amphibole asbestos fibers had the highest rates of illness. They say the only way to fully protect people against both amphibole and serpentine asbestos (the other major category) is banning asbestos completely. Asbestos Restrictions in the US The US EPA, the Department of Health … Continue reading Banning Asbestos Still Best Way to Prevent Mesothelioma
A recent study found no link between mesothelioma survival and exposure to pleural fluid. But that does not necessarily mean the link doesn’t exist. Pleural fluid is also called pleural effusions or “water on the lungs”. It is extra fluid that builds up around the lungs. It is common in people with heart failure, kidney or liver disease, pleural mesothelioma and some other kinds of cancer. Pleural effusions are usually treated as an uncomfortable mesothelioma symptom. Draining the fluid can help patients breathe easier. But researchers at Oxford University wondered whether the pleural fluid itself could shorten mesothelioma survival. In this study, the answer appears to be no. But the researchers warn this may not be the final word on … Continue reading Does Pleural Fluid Exposure Affect Mesothelioma Survival?